Compare Charles River Laboratories Intl. Inc (CRL) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Hut 8 Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $226.39 (market cap $11.14B), while Hut 8 Corp trades at $96.3 (market cap $11.07B). The key difference: Charles River Laboratories Intl. Inc and Hut 8 Corp are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| CRL | HUT | |
|---|---|---|
Market Cap | $11.14B | $11.07B |
Sector | Health | Technology |
52-Week High | $233.60 | $133.02 |
52-Week Low | $145.57 | $19.45 |
Enterprise Value | $14.00B | $11.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
HUT trades at $99.17, down 2.98% today, with a bearish technical signal. The company shows strong revenue growth potential but deep losses, with a net income margin of -109.77% in 2025. Recent news highlights its pivot to AI infrastructure, securing $16.8 billion in contracted revenue and closing a $4.25 billion investment-grade bond for data center projects.
Outlook is mixed: analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent negative cash flow from operations pose risks. The stock's near-term direction hinges on Q2 2026 earnings results and execution of its infrastructure expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
